The global Vitamin K2 market is valued at USD 372–458 million in 2025 and projected to grow at a CAGR of 10.9–13.7% (2026–2034), reaching USD 692–1,072 million by 2031–2034. MK-7 dominates due to its longer half-life and higher bioavailability, while MK-4 leads in pharmaceutical applications.

Growth drivers include aging populations, rising osteoporosis prevalence, and increasing evidence linking K2 to cardiovascular health and calcium regulation. Key applications: nutraceuticals (60%+), functional foods, and pharmaceuticals.

North America holds the largest share (35.18% in 2024), while Asia-Pacific is the fastest-growing region, driven by China's USD 42 billion 2026 forecast and Japan's natto consumption culture. Natural fermentation-based sources (67.28% market share) outpace synthetic alternatives.

Top players: NattoPharma, Kappa Bioscience, DSM. Future trends: personalized nutrition, plant-based formulations, and expanded clinical research.